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ABSTRACT 
 
Katherine A. Guilfoyle: MiRNA Profiling of Monocyte to Osteoclast Differentiation Reveals 
mRNA Targets Linked to Osteoclastogenesis 
(Under the direction of Salvador Nares) 
 
OBJECTIVES: To investigate differentially expressed microRNAs (miRNAs) and predicted 
target genes over 12 days of osteoclastogenesis.  METHODS: Leukophoresed buffy coats were 
obtained from healthy human donors (N=4) and CD14+ monocytes isolated.  Osteoclastogenesis 
was induced by culturing cells with sRANKL and M-CSF.  Freshly isolated monocytes and 
monocytes cultured with M-CSF alone were utilized as controls.  At 4 time points, RNA was 
isolated and miRNA levels interrogated using microarrays (N=36.)  MiRNA-mRNA target 
interactions for differentially expressed miRNAs were investigated using publically available 
algorithms.  RESULTS: MiRNA profiling revealed conserved and differentially expressed 
miRNAs; both novel and previously reported in osteoclastogenesis.  Several differentially 
expressed miRNAs shared predicted mRNA targets and given targets were targeted by multiple 
miRNAs.  CONCLUSIONS: MiRNA profiling osteoclastogenesis identified previously 
associated miRNAs and novel miRNAs not previously described in osteoclast differentiation.  
In-silico analysis reveals potential mRNA targets serving as candidates for future investigation, 
with possible future implications in human diseases.   
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A REVIEW OF OSTEOCLASTOGENESIS AND THE ROLE OF MICRORNA ON 
OSTEOCLAST DIFFERENTIATIONAND FUNCTION 
 
Introduction 
Osteoclasts are multinucleated cells derived from a myeloid lineage, which, through the process 
of osteoclastogenesis, differentiate from their hematopoietic precursors; 
monocytes/macrophages.
1
  Osteoclasts were originally confirmed to have a hematopoietic origin 
when osteopetrotic mice were apparently cured following injection of normal spleen cells
2
 and 
the hematopoietic origin was later confirmed in humans following a brother-to-sister bone 
marrow transplant.
3
 These observations that the presence of spleen or bone marrow cells together 
with stromal cells in fact yielded osteoclasts, was key in our understanding of 
osteoclastogenesis.
4
 These cells play a key role in the remodeling of bone, and thus the 
regulation of skeletal mass as resorptive cells; they are unique cells in that they resorb bone.
5
  
When imbalance occurs between the resorptive action of osteoclasts and the bone-forming action 
of osteoblasts, pathological conditions, such as osteoporosis may exist.  The individual with this 
disorder may experience pathological bone fractures due to a reduction in the density of skeletal 
mass.  A deep understanding of the osteoclast; how it is formed and its action, as well as the 
regulation of these processes is important in acquiring an understanding of such disorders, and 
may impact future therapeutic goals.  MicroRNAs (miRNAs) influence the differentiation 
process of osteoclasts on a genetic level.  Expression profiles obtained through miRNA analysis, 
showing which miRNAs, and thus, which likely target genes are up/down regulated throughout 
osteoclastogenesis allows for a deeper understanding of the differentiation process. 
2 
 
 
Differentiation 
In 1990, Udagawa et al. noted that marrow stromal cells or osteoblast progeny must be 
present for the in vitro maturation of macrophages to osteoclasts to occur.
1
  Two molecules are 
expressed that are necessary to promote osteoclastogenesis: macrophage colony-stimulating 
factor (M-CSF), a polypeptide growth factor, and receptor for activation of nuclear factor kappa 
beta (NF-κβ) (RANK) ligand (RANKL), a TNF-related cytokine.6, 7  M-CSF promotes the 
proliferation and survival of osteoclast progenitor cells, while RANKL prompts the 
differentiation through the osteoclast lineage and acts as both an activating and survival factor 
for mature osteoclasts.
8-10
  M-CSF
1
 binds its receptor c-FMs on osteoclast precursors and signals 
the survival and proliferation of the cells.  For osteoclastogenesis to occur, osteoclast precursors 
must be in contact with stromal cells or osteoblasts, 
1
 as RANK, found on osteoclasts and their 
precursors, interacts with RANKL, which resides on stromal cells.
7
 RANK-RANKL binding is 
essential for bone remodeling, as shown in mice deficient in either RANK or RANKL, sharing 
the same phenotype.
11-14
  RANK-RANKL interaction stimulates downstream signaling cascades, 
including mitogen-activated protein kinase (MAPK) pathway, phosphoinositide 3-kinase (PI3K) 
and NF-κβ.10, 15  RANKL is able to activate mature osteoclasts in vitro in a dose-dependent 
manner and activate pre-existing osteoclasts in vivo; rapidly leading to bone resorption.
11, 16, 17
  It 
leads to induction of osteoclastogenic transcription factors c-Fos, fos-related antigen 1 (Fra-1) 
and cytoplasmic, calcineurin-dependent nuclear factor of activated T-cells cytoplasmic 1 
(NFATc1.)
10, 18-21
  M-CSF and RANKL are both necessary for the promotion of 
osteoclastogenesis, and they are needed to induce expression of genes that encode tartrate-
resistant acid phosphatase (TRAP), cathepsin K (CATK), calcitonin receptor and the B3-integrin
7
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so that mature osteoclasts may develop.
11
  Simon et al. noted in 1997 that overexpression of 
osteoprotegrin (OPG) blunts osteoclastogenesis in mice, and those animals lacking OPG were 
noted to have accelerated osteoclastogenesis and thus developed osteoporosis
22
.  OPG, a secreted 
TNFR-related protein which regulates density and mass of bone, 
22, 23
 is a “decoy” receptor, 
which competes with RANK on osteoclasts and their precursors for RANKL.
7
  The amount of 
bone resorbed is dictated by a shift in balance between RANKL, which stimulates 
osteoclastogenesis; and OPG, the inhibitor.
24
 As further evidence that the protein complex, NF-
κβ plays a key role in osteoclastogenesis, mice that lack the p50 and p52 subunits of the complex 
develop osteopetrosis due to the inability of osteoclasts to differentiate from macrophages.
25
 The 
survival of the mature osteoclast is regulated by hormones and cytokines
11, 26
 and it has been 
shown that RANKL and interleukin (IL)-1 increase survival time both in vitro and in vivo; 
possibly due to their ability to induce NF-κβ.27, 28 
Osteoclast Action 
Osteoclasts are unique, multinucleated, bone resorptive cells, which degrade bone tissue 
in a multistep process.  With its “ruffled membrane,” the osteoclast is able to polarize on bone, 
forming a resorptive organelle, which is only present when the cell is attached to bone tissue.
29
 
Polarization of the osteoclast cell body occurs in response to RANK activation by RANKL
16
 
leading to structural changes, including the rearrangement of the actin cytoskeleton and the 
formation of a tight junction, a sealed compartment between the bone and basal membrane of the 
cell.
11, 16
  The export of hydrogen ions leads to the acidification of this “vacuole” 11, 30 and lytic 
enzymes, such as tartrate resistant acid phosphatase (TRAP) and pro-cathepsin K (pro-CATK) 
are also released into the pit; or Howship’s lacunae.11  As the osteoclast erodes bone, degradation 
4 
 
products are produced, including fragments of collagen and solubilized calcium and phosphate; 
which after processing by the osteoclast, are released into circulation.
11
   
Several genes or loci regulate osteoclastogenesis and the activation of the mature 
osteoclast in either positive or negative fashions.  This has been shown through both naturally 
occurring mutations and targeted knockout mutations in animals and humans.
11, 31, 32
  Disruption 
of gene activity may lead to osteopetrosis or osteopenic conditions.  The effects of genes may be 
exerted at various steps of osteoclast development and activation; for example, PU.1 and 
op/CSF-1 act during the formation and survival of osteoclast precursor cells, while other genes, 
such as RANK, p50/p52 rel and fos affect the differentiation of these precursor cells towards a 
multinucleated cell,
11
 as discussed previously.  PU.1 encodes a transcription factor of the E26 or 
ETS family and activates gene expression during myeloid cell development, while op/CSF-1, 
encodes a key cytokine to macrophage production, differentiation and function.  Other genes, 
such as src, oc/Tcirg and CATK affect the actions of the mature osteoclast, such as its ability to 
adhere to bone and perform lytic functions
11
. 
Disease Pathogenesis 
In health and in young adults, the destruction and formation of bone is balanced, with 
osteoclasts resorbing bone in approximately 3 weeks per site, and osteoblasts forming new bone 
tissue in approximately 3-4 months.
29
  This process is normal and necessary for bone to carry out 
its supportive and mechanical functions.  The influences by mechanical use
33, 34
 as well as the 
likely influence of central homeostatic factors
35
 help guide the resorption and rebuilding of bone, 
to maintain a steady state.
36
 A majority of skeletal diseases occurring in adults are due to an 
excess of osteoclast action, which leads to an imbalance in the bone remodeling process, such 
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that resorption is increased.
36
 Such skeletal diseases include osteoporosis, periodontal disease, 
rheumatoid arthritis, multiple myeloma and metastatic cancers.
11
    
Osteoporosis is a systemic skeletal disease which is characterized by a decrease in bone 
mass, leading to increased bone fragility and risk of fracture.
37
  Approximately 70 million 
individuals worldwide are at risk, and bone fractures in those with osteoporosis may potentially 
be life-threatening occurrences.
11
 The peak bone mass is reached in the third decade of life; and 
although a ‘physiologic’ age-related change, the mass decreases approximately 0.5% per year.38, 
39
  Several factors, such as genetics, nutrition and physical activity increase the risk of fractures 
along with age-related bone loss; however, this bone loss alone does not necessarily predispose 
one to fractures.
39, 40
  Two types of osteoporosis have been classified; due to pathophysiology 
and regions affected: post-menopausal osteoporosis and senile osteoporosis.  Post-menopausal 
osteoporosis is due to decreased estrogen levels in post-menopausal women, it mainly affects 
trabecular bone, and is associated with vertebral and wrist fractures.
39, 41
 Estrogen helps to 
regulate the activity of osteoclasts, and so, low estrogen levels during menopause facilitate the 
differentiation and activity of osteoclasts.  Simultaneously, available osteoblast numbers, as well 
as osteoblastic activity is decreased due to hormone-independent mechanisms.
39, 42
  Senile 
osteoporosis occurs at a similar rate in both sexes, usually after the sixth decade of life, and 
affects cortical bone most frequently; predisposing individuals to hip fracture.
39, 43
  In senile 
osteoporosis; osteoclast activity levels are high and osteoblast availability/activity is reduced due 
to decreased osteoblast differentiation from mesenchymal cells, which have undergone a shift to 
differentiate into adipocytes; an increasing marrow fat infiltration that affects survival and 
function of osteoblasts; and high levels of osteoblast apoptosis.  These mechanisms, which occur 
in both males and females, affect the aging, osteoporotic bone by reducing its capacity to repair 
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areas that have weakened; and so, leaving it predisposed to the occurrence of fracture.
39, 43, 44
 
Changes in cell-to-cell communication which occur with age, also affect osteoporotic bone, 
making it more fracture-prone; the most common changes being an increase in RANKL, a 
decrease in OPG
45
 and an increased level of sclerostin,
46
 which is released by osteocytes and 
inhibits osteoblast activity.
39
   
Osteopetrosis is condition which is characterized by abnormally high levels of 
mineralized bone and cartilage; and occurs when the development and/or function of mature 
osteoclasts is negatively affected.
11
  There are either a decreased number of osteoclasts or the 
cells are defective in function.
47
  The condition was first reported in 1904 by Albers-Schönberg, 
who described it as “marble bone disease.”47, 48 A variety of manifestations result from 
osteopetrosis, ranging from mild symptoms to death at an early age.
47
  The bone marrow space 
may become crowded, leading to inability to produce red blood cells, white blood cells and 
platelets,
47, 49, 50
 thus resulting in anemic conditions and chronic infections
47
 due to these reduced 
blood cell counts.  These effects upon the bone marrow are usually noted in the autosomal 
recessive form of osteopetrosis; with other manifestations including hearing loss, blindness, 
macrocephaly hepatosplenomegaly, short stature, abnormalities in the dentition and failure to 
thrive Children affected by this condition have a 98-99% mortality rate by the age of 10 years.
47, 
49, 50
  An autosomal dominant form exists, with less severe manifestations and a typically later 
diagnosis.  Loss of vision with optic atrophy is a common neurological finding, occurring due to 
bony encroachment upon the optic nerve
47, 49, 51
  Pathological bone fractures occur as well, and 
this finding typically leads to the diagnosis in later childhood or adulthood.
47, 49, 51
   One must 
keep in mind that the excess bone found in osteopetrosis is due to lack of osteoclastic action, so 
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the bone present is not of the same quality as that formed through normal resorption and 
remodeling processes.  Fractures occur due to the bone quality, not quantity. 
Periodontal disease and peri-implant bone loss are affected by the actions of osteoclasts.  
In periodontal disease, periodontal pathogens trigger inflammatory and immune responses, 
which affect the clinical outcome of the condition; such as loss of alveolar bone and connective 
tissue attachment.  Inflammatory mediators trigger the bone resorption and proteases which 
degrade the extracellular matrix, leading to tissue destruction.
52-56
  To this day, much remains 
unknown with regards to the activation of osteoclasts as it relates to periodontal disease 
pathology, and a better understanding is key in the evolution of new treatments for 
periodontitis.
57
  Garlet et al. 2004 investigated expression patterns of mRNAs which encoded for 
matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinase (TIMPs), RANKL and 
OPG by real-time polymerase chain reaction (RT-PCR) and correlated patterns with cytokine 
expression within gingival biopsies from healthy subjects and those with chronic and aggressive 
periodontitis.  The study noted that the aggressive and chronic periodontitis groups displayed 
similar levels of expression of MMPs, RANKL and TNF-α; however, the expression of TIMPs, 
OPG and IL-10 were higher in those with chronic periodontitis.  The authors suggest that the 
higher expression of OPG in those with chronic periodontitis (compared to those with aggressive 
periodontitis) could perhaps partially control the alveolar bone loss driven by RANKL, reducing 
the progression rate and severity of this form of periodontal disease.  Lower expression of OPG 
in aggressive periodontitis would then be a potential influence of more severe disease
56
 with 
regard to progression rate of bone loss.  The study concludes that the pattern of cytokines 
expressed in the two disease forms affects the progression and severity of disease through effects 
upon MMP/TIMP and RANKL/OPG balance in the tissues.
56
  Niwa et al. recently examined the 
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effects of chemoattractants in periodontitis tissues upon osteoclast chemotaxis using the EZ-
TAXIScan™ method, which measures the chemotactic speed and angle through a concentration 
gradient between a glass plate and thin microfabricated silicon chip, or channel.
57
  The 
chemotactic responses of day 3 and 6 osteoclasts to several chemoattractants expressed in 
periodontitis tissue were measured, including MCP-1, MIP-1α, RANTES, SDF-1α and C5a.  The 
highest chemotactic response of day 6 osteoclasts, with regards to chemotactic speed, direct 
migration and percentage of chemotactic cells, was noted to be towards C5a.  Furthermore, the 
speed of chemotaxis towards C5a increased from day 3 to day 6; these findings were in 
agreement with Ignatius et al., who found that the expression of the C5a receptor increases 
throughout osteoclast differentiation.
57, 58
  Previous studies have shown that Porphyromonas 
gingivalis produces Arginine-specific protease gingipain, which results in increased C5a 
production.
57, 59, 60
  C5a is reported to inhibit neutrophil immune activation when within a range 
of 10-100nm
61-63
 and Niwa et al. reported that 100nm of C5a induced the highest chemotactic 
response for the day 6 osteoclasts.  The authors state that a P. gingivalis-induced increase in C5a 
must play a role in the progression of periodontitis by suppressing the immune response of 
neutrophils while increasing the chemotaxis of osteoclasts.
57
  Lastly, the Niwa et al. study found 
that H-8135, a selective C5a receptor antagonist inhibits both day 3 and 6 osteoclast chemotaxis 
towards C5a.  Antagonistic activity inhibiting the recruitment of osteoclasts would thus inhibit 
the bone resorption by osteoclasts;
57
 fueling interest in such antagonists for future therapeutic 
methods.   
A recent study by Kadkhodazadeh et al. investigated the possibility of the RANKL gene 
being a genetic determinant for peri-implantitis.
64, 65
  The study found that a particular genotype 
(CT) of the rs9533156 TANKL gene polymorphism was significantly associated with peri-
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implantitis in an Iranian population, and suggested that it could be considered as a genetic 
determinant for peri-implantitis.
65
  Rakic et al. studied the levels of biomarkers in gingival 
crevicular fluid associated with osteoclastogenesis (sRANKL, RANK and OPG) in subjects with 
peri-implantitis and compared them to levels in those with healthy peri-implant sites and severe 
chronic periodontitis sites.  When compared to healthy sites, levels of sRANKL, RANK and 
OPG were all significantly higher in peri-implantitis sites, although the sRANKL/OPG ratios 
were not statistically significantly different.  When compared to periodontitis sites, RANK was 
significantly higher in peri-implantitis sites; however, sRANKL and the sRANKL/OPG ratio 
were significantly higher in periodontitis sites.  The authors concluded that while there were 
differences in the patterns of the biomarkers in comparison with periodontitis sites, all three were 
associated with peri-implant tissue destruction.
66
 
MicroRNA Action in Osteoclastogenesis 
As previously discussed in this review, the regulation of osteoclastogenesis is influenced 
by M-CSF and RANKL, as well as sex steroids, parathyroid hormone (PTH), vitamin D, insulin-
like growth factor-1 (IGF-1), calcitonin, prostaglandins
5, 67
 and transcription factors, such as c-
fos, PU.1, NFκβ (p50 and p52 subunits) and nuclear factor of activated T cells cytoplasmic 1 
(NFATc1).
18, 21, 68-71
  Recent studies have shown that microRNAs (miRNAs) are also necessary 
for osteoclastogenesis, as they influence osteoclast differentiation, function and survival.
71
 Gene 
silencing studies of DGCR8, Dicer and Ago2 have verified the role of miRNAs in osteoclast 
differentiation and function; as these genes are needed for miRNA homeostasis.
72-74
  
MiRNAs are small, non-coding, single-stranded RNAs that measure approximately 19-25 
nucleotides in length, and which have been found to regulate several pathways in the cell cycle, 
including differentiation, proliferation, apoptosis and tumorigenesis.
75
 MiRNAs regulate the 
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expression of an estimated 8000 genes, which amounts to approximately 30% of the human 
genome.
76-78
 Each miRNA may suppress multiple genes; approximately 200, on average; and a 
single mRNA can be targeted by multiple miRNAs.
77, 79-81
  In eukaryotes, miRNAs form 
imperfect hybrids, as there is only partial complementarity, with the 3’ untranslated region 
(UTR) sequences of target mRNAs, enabling regulation.  As a result, translational repression 
and/or mRNA degradation occurs.
82
  MiRNAs have been shown to be associated with actively 
translating mRNA
83
 and several mechanisms may contribute to miRNA-mediated regulation of 
genes; which may vary depending on the gene, cell and condition.
84
  
Particular miRNAs have been identified as influential in osteoblast differentiation and 
bone formation; while there is limited knowledge regarding the regulatory role of miRNAs in 
osteoclastogenesis.  MiRNAs involved in osteoblast differentiation and bone formation include, 
but are not limited to
71
 miR-125b,
85
 miR-26a,
86
 miR-133 and miR-135,
87
 miR-204/211,
88
 miR-
29a,
89
 miR-141 and miR-200a,
90
 miR-206,
91
 miR-29b,
92
 miR-210,
93
 miR-196a
94
 and miR-
2861.
95
  
 While miRNA function in osteoclastogenesis is not yet completely understood; several 
miRNAs have been noted to play a role.  Sugatani et al. studied the miRNA signature of 
RANKL-induced osteoclastogenesis and showed that 38 miRNAs were elevated and 33 were 
downregulated.
96
  MiRNAs with a known role in the differentiation and function of osteoclasts 
include miR-21, miR-223, miR-155 and miR-146a.  The overexpression of miR-21 leads to 
promotion of c-Fos (a transcription factor which is critical in osteoclastogenesis) through the 
down-regulation of programmed cell death 4 (PDCD4) protein levels, via repression removal 
from c-Fos.
97
  Thus, a positive feedback loop exists between miR-21, c-Fos and PDCD4; related 
to regulation of osteoclastogenesis.
96
 Sugatani et al. noted that miR-21 was robustly stimulated in 
11 
 
RANKL-induced osteoclastogenesis.
71, 97
   MiR-223 has been shown to stimulate the expression 
of macrophage colony-stimulating factor receptor (M-CSFR); however, overexpression of pre-
miR-223 has been found to block the formation of osteoclasts.
98
 Induction of PU.1 by M-CSF, 
will stimulate the expression of this miRNA, which thus down regulates NFI-A, which is needed 
to up-regulate M-CSFR levels.  Increased expression levels of PU.1, microphthalmia-associated 
transcription factor (MITF) and c-Fos are induced by M-CSF and 
99
RANKL through the up-
regulation of M-CSFR and RANK.
73
   
Sugatani et al. used chemically modified antisense oligonucleotides (ASOs), also known 
as antagomirs, which are complementary to specific miRNAs to investigate how essential the 
roles of miR-21 and mir-223 were to osteoclastogenesis.  Antagomirs were developed for 
investigative and therapeutic approaches to silencing miRNAs in vivo.  They are cholesterol-
conjugated, single-stranded RNA analogs, which can transiently interfere with miRNA.
71, 100-102
   
The ability of antagomirs as specific silencers of endogenous miRNAs have made them useful in 
investigating gene functions both in vitro and in vivo
71, 99, 103
 and in clinical trials via antisense 
therapeutics.
71, 104, 105
  Sugatani et al. transduced bone marrow-derived monocyte/macrophage 
precursors (BMMs) with antisense miR-21-containing lentivirus and found extreme up-
regulation of PDCD4, which is targeted by miR-21. Remarkable down-regulation of RANKL-
induction of c-Fos phosphorylation, and expression of NFATc1 and cathepsin K protein were 
noted in cells with reduced levels of miR-21 due to the silencing effect.  Thus, normal expression 
of miR-21 is relevant to osteoclastogenesis.
71, 97
  The same group investigated the role of miR-
223 in osteoclastogenesis using antagomirs.  It was found that the inhibition of miR-223 induced 
down-regulation of TRAP-positive osteoclast formation.  Additionally, NFI-A levels were up-
12 
 
regulated, which resulted in a decrease of M-CSFR levels.  It was suggested that miR-223 is 
essential for osteoclastogenesis as well, via expression of M-CSFR.
71, 73
  
MiR-155 and miR-146a have been found to significantly down-regulate MITF and 
NFATc1, respectively, both of which play important roles in osteoclast differentiation.
106, 107
  
Zhang et al. studied miR-155 targeting of suppressor of cytokine signaling 1 (SOCS1) and MITF 
in a murine model.  It has been previously shown that miR-155 is induced by IFN-β and that 
IFN-β suppresses the differentiation of osteoclasts.10, 107, 108   SOCS1 and MITF promote 
osteoclast differentiation by inhibiting IFN-β downstream signaling and by cooperating with 
NFATc1,
10, 11, 109
 respectively.
10
  Zhang et al. found that mir-155, which is an IFN-β inducible 
miRNA, can target SOCS1 and MITF and mediate the suppressive effect of IFN-β on 
osteoclastogenesis.
10
  
The effects of miR-146a overexpression upon osteoclastogenesis were studied by Nakasa 
et al. in 2001.  This study showed in a murine model that miR-146a led to a significant down-
regulation of c-Jun, NFATc1, PU.1 and TRAP.  Results further suggested that one mechanism of 
osteoclastogenesis suppression was the down-regulation of TNF receptor-associated factor 6, 
(TRAF6), a validated target of miR-146a
110
  and critical signaling molecule in RANKL-mediated 
osteoclastogenesis.
111-113
  
Conclusion 
The differentiation of monocytes to multinucleated osteoclasts is a complex process 
affected by several different transcription factors and genes.  As this review discusses, several 
pathological conditions arise from a lack of balance between the function of osteoblasts, forming 
bone and osteoclasts resorbing bone.  A deeper understanding of the process of 
13 
 
osteoclastogenesis will enable further treatment modalities to be developed for individuals 
suffering from these diseases, and perhaps help in prevention someday.  The small miRNA, only 
approximately 22 nucleotides in length, can have major impacts upon osteoclastogenesis and 
disease pathogenesis through the regulation of gene targets.  Studies have identified several 
miRNAs that play roles in osteoblast and osteoclast differentiation and function; however, as 
miRNAs have been studied for only a short period of time thus far, further research into the 
identification and characterization of additional miRNAs is needed   The future will likely hold 
vast and exciting discoveries through the investigation of miRNAs, which may deeply impact 
medical interventions. 
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MIRNA PROFILING OF MONOCYTE TO OSTEOCLAST DIFFERENTIATION 
REVEALS MRNA TARGETS LINKED TO OSTEOCLASTOGENESIS 
 
 
Introduction 
 
Osteoclastogenesis is the process by which bone resorptive cells, osteoclasts, differentiate 
from their hematopoietic precursors; monocytes and macrophages.
1
  The role osteoclasts play in 
bone remodeling is important for the regulation of skeletal mass
5
 and in keeping balance with the 
action of bone-forming cells, osteoblasts.  In order for osteoclasts to differentiate from their 
precursors, two molecules must be expressed: macrophage colony stimulating factor (M-CSF), 
which is a polypeptide growth factor; and receptor for activation of nuclear factor kappa β (NF-
κβ) (RANK) ligand (RANKL), which is a TNF-related cytokine.6, 7  These molecules are 
necessary as M-CSF promotes both the proliferation and survival of osteoclast progenitors and 
RANKL prompts the differentiation along the osteoclast lineage, behaving as an activating and 
survival factor for mature osteoclasts.
8-10
   RANK on the osteoclast must interact with RANKL, 
which resides on the stromal cells, for osteoclastogenesis to occur.
7
  This interaction stimulates 
downstream signaling cascades, which include the mitogen-activated protein kinase (MAPK) 
pathway, phosphoinositide 3-kinase (PI3K) and NFκβ.10, 15  RANKL induces osteoclastogenic 
transcription factors c-Fos, fos-related antigen 1 (Fra-1) and cytoplasmic, calcineurin-dependent 
nuclear factor of activated T-cells cytoplasmic 1 (NFATc1.)
10, 18-21
  Together, M-CSF and 
RANKL promote osteoclastogenesis by also inducing the expression of genes that encode 
tartrate-resistant acid phosphatase (TRAP), cathepsin K (CATK), calcitonin receptor and the B3- 
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integrin
7
, enabling mature osteoclasts to develop.
11
  These and many other molecules, including 
hormones and cytokines,
11, 26
 do affect the differentiation and survival of the osteoclast.  
Through genetic mutations, occurring both naturally and through targeted knockouts, 
several genes or loci have been found to regulate osteoclastogenesis, as well as the activation of 
the mature osteoclast.
11, 31, 32
  Genes may exert their effects at various stages of osteoclast 
development and activation, such as the formation and survival of precursor cells, differentiation 
to osteoclasts, or survival of the mature osteoclast.
11
  Disruption of gene activity may influence 
occurrence of pathological conditions.  Conditions such as osteoporosis and osteopetrosis may 
occur when an imbalance exists between osteoclast and osteoblast activity.  A deeper 
understanding of the process of osteoclastogenesis may help in one day developing new 
therapeutic or preventative interventions for such conditions.  The study of microRNAs 
(miRNAs) may be an informative path to gaining better understanding of osteoclastogenesis and 
bone resorptive disease pathogenesis. 
MiRNAs are small, non-coding, single-stranded RNAs measuring approximately 19-25 
nucleotides in length and have been found to regulate several cellular pathways.
75
  They have 
been found to regulate the expression of an estimated 8000 genes, or approximately 30% of the 
human genome.
76-78
  In eukaryotes, miRNAs form imperfect hybrids with their targets, the 3’ 
untranslated region (UTR) sequences of mRNAs.
82
  With this partial complementarity, a miRNA 
may target and suppress multiple genes; approximately 200 on average; and a single mRNA may 
be targeted by multiple different miRNAs.
77, 79-81
  MiRNAs have been shown to be necessary for 
osteoclastogenesis, as they influence the differentiation, function and survival of osteoclasts.
71
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Several miRNAs have been identified as being influential in osteoblast differentiation 
and bone formation
71
, including, miR-125b
85
, miR-26a
86
, miR-133, miR-135
87
, miR-204/211
88
, 
miR-29a
89
, miR-141, miR-200a
90
, miR-206
91
miR-29b 
92
, miR-210
93
, miR-196a
94
 and miR-
2861
95
.  Fewer studies have investigated the role of miRNAs in osteoclastogenesis, although 
some have been identified.  MiRNAs with a known role in the differentiation and function of 
osteoclasts include, but are not necessarily limited to miR-21, miR-223, miR-155 and miR-146a. 
Mir-21 overexpression has been found to lead to the promotion of C-Fos
97
, a key 
regulator in the osteoclast lineage determination.
18
  MiR-21 was also found to be robustly 
stimulated in RANKL-induced osteoclastogenesis.
71, 97
  MiR-223 has been shown to stimulate 
the expression of M-CSFR; however, overexpression of pre-miR-223 blocks the formation of 
osteoclasts.
98
  Inhibition of miR-223 was noted to down-regulate TRAP-positive osteoclast 
formation and decrease M-CSFR levels.
71, 73
  Zhang et al. found that miR-155, an interferon-β 
(IFN-β) inducible miRNA, can target suppressor of cytokine signaling 1 (SOCS1) and 
microphthalmia-associated transcription factor (MITF) and mediate the suppressive effects of 
IFN-β on osteoclastogenesis.10  Overexpression of miR-146a has been shown to lead to a 
significant down-regulation of c-Jun, NFATc1, transcription factor PU.1 and TRAP.  The down-
regulation of TNF receptor-associated factor 6 (TRAF6), a validated target of miR-146a and 
critical signaling molecule in RANKL-mediated osteoclastogenesis
111-113 
has been found to 
suppress osteoclastogenesis.
110, 111, 113, 114
   
The aim of this study was to investigate the miRNA profiles of monocyte-to-osteoclast 
differentiation using microarrays over a 12 day period.  The secondary aim was to identify 
differentially expressed miRNAs not previously associated with osteoclast differentiation and 
function and identify their predicted targets.   
17 
 
Materials and Methods 
 
Isolation of Monocytes and Differentiation into Macrophages and Osteoclasts 
 
 Peripheral blood mononuclear cells (PBMCs) were collected from buffy coats 
derived from four healthy, human, independent donors (Oklahoma Blood Institute, Oklahoma 
City, OK) by density gradient centrifugation, using Ficoll-paque (Amersham, Uppsala, Sweden.)  
Monocytes were isolated using CD14 MicroBeads (Miltenyi Biotec, Auburn, CA) following the 
manufacturer’s instructions and cultured as previously described115, 116  Briefly, the isolated 
monocytes are plated in duplicate onto 24-well tissue culture-treated plates (BD Biosciences, San 
Jose, CA) at a density of 1.2 x 10
6 cells/cm2 in media consisting of RPMI (Cellgro, Manassas, 
VA) at 37 C, 5 % CO2.  10% heat-inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, 
CA) and 50µg/mL gentamycin (Sigma, St. Louis, MO) was added after 2 hours.
115, 116
  Media 
was replaced every 3 days throughout the experiment.   
 For osteoclast differentiation, monocytes were cultured in the presence of a33ng/ML M-
CSF and 100ng/ML sRANKL (Peptrotech, Offenbach, Germany) over 12 days.  Media was 
replaced every 3
rd
 day with fresh media containing M-CSF and sRANKL.  Freshly isolated 
monocytes and monocytes cultured in the presence of M-CSF alone were utilized as controls.  
Day 0, 1, 3, 6 and 12, cultures were used for the study.   
Flow Cytometry 
For phenotyping of monocytes and macrophages, day 0 monocytes and day 6 
macrophages were examined via FACS analysis with regards to the antibodies against CD14
FITC
, 
CD86
FITC
 and CDw93
FITC. 
 Antibodies were purchased from AbD Serotec (Raleigh, NC) and 
used in the following dilutions and formats: CD14
FITC
 1/400 dilution, IgG1, mouse α-human; 
CD86
FITC
 1/200 dilution, IgG1, mouse α-human and CDw93FITC 1/200 dilution, IgG2bκ, mouse 
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α-human.  Cells were transferred to a 96-well V bottom plate (BD Falcon), kept on ice for 10 
minutes and a pipette tip was used to scrape and vigorously pipette up and down.  Plates were 
centrifuged at 1600rpm for 5 minutes and re-suspended in 200µL of FACS buffer (ice-cold PBS, 
2mM EDTA, 0.5% FBS.)  Centrifugation at 1600rpm was repeated for an additional 5 minutes, 
then cells were re-suspended in 50µL of FcR block (1/200 dilution, Miltenyi Biotech, α-human.)  
50µL of the respective antibodies were diluted 1/100, 50µL of the respective antibody was then 
added (2x final concentration for 15 minutes.)  Centrifugation was repeated at 1600rpm for 5 
minutes.  Cells were re-suspended in 200µL of FACS buffer, centrifugation repeated at 1600rpm 
for 5 minutes and cells re-suspended once again in 200µL of 4% paraformaldehyde (PFA) (USB, 
Affymetrix.)  All samples were analyzed by FACS using DellQuest software and data analyzed 
using FloJo software (TreeStar Inc., Ashland, OR, USA) 
 IgG is purified and conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC)- liquid. 
CD14 is a glycoprotein containing multiple leucin-rich repeats, and is found anchored to the cell 
membrane via glycosylphosphatidylinositol
117
 and in a soluble form.
118
  CD14 is expressed on 
the surface of monocytes and macrophage, as well as some non-myeloid cells
119
 and serves as a 
pattern recognition receptor
120, 121
 for several ligands, including leukopolysaccharide (LPS.)  In 
coordination with other proteins, CD14 helps to mediate the innate immune response to LPS.
122
  
CD86 is expressed on antigen presenting cells (APCs) and provides co-stimulatory signals for 
the activation and survival of T-cells.  CD86 has been shown to be expressed on freshly isolated 
monocytes
123
 and serves as a co-stimulatory ligand, along with CD80, for CD28/CTLA-4.
124
  
CDw93 is used to mark differentiation of monocytes to macrophages as expression ceases 
throughout the differentiation process and is not expressed on macrophages.
125
  Previously 
known as C1qRp, CD93 has been shown to play a role in cell adhesion.
126
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TRAP Staining 
 
Tartrate resistant acid phosphatase (TRAP) staining was performed on day 0, 3, 6 and 12 
using 10mg Naphtol AS-MX phosphate, 1mL dH2O, 0.2M sodium acetate, 0.2M acetic acid, 
0.3M sodium tartrate, 0.1M acetate buffer and TRAP buffer (pH = 5) at 37°C.  Following 
removal of medium and washing with PBS, cells were fixed with 10% glutaraldehyde for 15 
minutes at 37°C.  Following two subsequent washes with PBS, TRAP stain was added for 5 
minutes at 37°C.  TRAP stain was removed, wells washed with PBS and cells observed using 
light microscopy at 20x magnification, to confirm differentiation to osteoclasts. 
 
OsteoLyse
TM
 Assay 
 
The OsteoLyse
TM
 Assay was performed on days 3, 6, and 12.  Differentiation was 
confirmed by microscopy, TRAP + staining and bone resorption using the Osteolyse™ bone 
resorption kit (Lonza, Walkersville, MD)  according to the manufacturer’s recommendations.  
Cells in media containing M-CSF and sRANKL were seeded at a density of 4x10
5
 cells/cm
2
 onto 
the OsteoLyse
TM
 Cell Culture Plate.  The macrophages (cultured in the absence of sRANKL) 
served as a control group for comparison.  Cells were cultured for 6 days, then 200µL of 
Fluorophore releasing Reagent was placed in each well of the included black 96-well assay plate.  
10µL of cell culture supernatant was added to these wells and after mixing, fluorescence was 
measured for each well with excitation of 340nm and emission at 615nm.   
Cell Viability 
Viability was assayed using CellTiter 96
®
 Aqueous One Solution Reagent (Promega, 
Madison, WI, USA) following the manufacturer’s guidelines.  Briefly, cells were plated onto a 
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96-well plate and 20µL of reagent was added to each well.  Following 2 hours of incubation at 
37°C, the absorbance was recorded at 490nm using a 96-well plate reader. 
Total RNA Isolation 
  
 At the indicated collection points, the supernatant was removed and stored separately at    
-80
◦
C.  Total RNA was isolated using the miRNeasy mini kit (Qiagen, Gaithersburg, MD) 
according to manufacturer’s instructions.  Isolation was performed on 12 samples 
simultaneously.  Total RNA concentrations and integrity was evaluated using a NanoDrop 
Spectrophotometer (Thermo Scientific, Wilmington, DE) and Bioanalyzer (Agilent, Foster City, 
CA), respectively.   
MicroRNA Arrays 
 
RNA samples (N=36) were randomly labeled 1-36 (for blinding purposes) and sent to 
Exiqon Services (Vedbaek, Denmark) for microarray analysis.  RNA quality was confirmed by 
Exiqon Services.  225ng of RNA were labeled using the miRCURY LNA
TM
 microRNA Hi-
Power Labeling Kit Hy3
TM
/HY5
TM
 and subsequently hybridized on the miRCURY LNA
TM
 
microRNA Array (7
th
) MicroRNA levels were probed using miRCURY LNA
TM
 microRNA 
Arrays following the procedures described by the manufacturer.   
Statistical Analysis 
 
Statistical analyses of the microarray data were provided by Exiqon services.  P-values 
were corrected for multiple testing by the Benjamini and Hochberg adjustment method.  Genes 
that have been found to be significant via the one-way ANOVA test were subjected to the 
Tukey’s ‘Honest Significant Difference’ test, thus determining which groups contribute the 
greatest to the significant difference noted.  However, we performed Bonferroni correction upon 
the original data and found the selection of miRNAs to be more stringent using this format.  With 
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Benjamini and Hochberg adjustment and Tukey’s ‘Honest Significant Difference,’ a subset of 
219 miRNAs (p<0.05) were identified out of the 422 total miRNAs analyzed.  Following the 
Bonferroni correction using the original data, 69 miRNAs were found to be significantly 
differentially expressed.  Fold change was calculated using the minimum and maximum group 
averages, indicating that a fold change was calculated from the greatest change in signal 
throughout the differentiation process, not necessarily from day 0-12, although in some miRNAs, 
the greatest change occurred from day 0 to day12.  Thus, a significant change in expression 
levels occurred between two time points within the differentiation period. 
Network Analysis 
Ingenuity
®
 Pathway Analysis was used to examine networks relating the miRNAs which 
were determined to be differentially expressed during osteoclast differentiation (Bonferroni 
p<0.05).  All miRNAs which had calculated Bonferroni p<0.05 were input and this analysis was 
not limited to those with a signal intensity in the range of 7.5-14.5, nor a 2-fold change 
requirement. 
Target Selection 
The miRNAs deemed to be significantly differentially expressed, as per Bonferroni 
correction were further investigated.  Many of these miRNAs were also noted in the top 30 
(ranked by p-value) differentially expressed miRNAs throughout differentiation from monocytes 
to osteoclasts which were provided from Exiqon Services in their data analysis summary.  Prior 
to target selection, Exiqon Services recommended limiting selection to miRNAs with a fold 
change of at least 2-fold as well as average signal intensity in the range of 7.5-14.5.  In-silico 
analysis was performed using MiRWalk
127
 (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/) Predicted Targets module to investigate mRNA targets for 
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these miRNAs.  Genes noted to be predicted targets of a significant, differentially expressed 
human miRNA were investigated for involvement in cell differentiation or specifically 
osteoclastogenesis and osteoclast function; if the status as a predicted target was agreed upon by 
a minimum of three of the four following database programs: miRWalk, miRanda (August 2010 
release, http://www.microrna.org/microrna.do), miRDB (April 2009 release, 
http://mirdb.org/miRDB/), and TargetScan Version 5.1 (http://targetscan.org/).   
Results 
 
Examination of the flow cytometry data reveals that macrophages had differentiated from 
peripheral blood monocytes.  Figure 1 shows the phenotyping results comparing day 0 
monocytes and day 6 monocytes (cultured in M-CSF following monocyte isolation.)  Cultures 
tested positive for CD14, CD86 and CD93.  Data represented in red signifies unstained sample, 
blue coloring represents control for the specific isotype; together these account for background 
noise and control.  Green represents stained sample and the amount of cells positive for the 
specific cluster of differentiation.  Both freshly isolated monocytes and those cultured with M-
CSF were CD14+ and CD86+; however, only the monocytes were CD93+.  This is consistent 
with differentiation of the monocytes cultured in M-CSF to macrophages as these latter cells are 
CD93-.  This phenotyping data confirmed the presence of macrophages through successful 
differentiation.    
 We next sought to confirm the differentiation of monocytes cultured with M-CSF and 
sRANKL to osteoclasts.  Figure 2 displays the TRAP staining data for day 0 monocytes and 
those cultured in M-CSF and sRANKL at days 3, 6 and 12.  TRAP is a glycosylated monomeric 
metalloenzyme, which is expressed in mammals,
128
 which tends to be localized within the ruffled 
border, lysosomes, Golgi cisternae and vesicles of the osteoclast.
129
  The red stain becomes more 
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predominant with differentiation to osteoclasts and the multinucleated osteoclasts can be seen 
under closer higher magnification.  Figure 3 shows day 12 osteoclasts at 40x magnification, 
differentiated from the peripheral blood monocytes, clearly noting multiple nuclei and the 
fingerlike processes that make up the ruffled border, the structure that facilitates delivery of 
enzymes and thus creates an acidic environment for bone degradation.    
The OsteoLyse™ Assays were performed on days 3, 6 and 12 for cells cultured for the 
macrophage lineage (M-CSF) as well as the osteoclast lineage (M-CSF +sRANKL.)  This assay 
quantitatively measures in vitro osteoclast-mediated bone resorption by directly measuring the 
release of matrix metalloproteinases into the resorption lacuna of the osteoclast.
130
  The release 
of Eu-labeled collagen fragments was measured after the cell culture supernatant was added to 
Fluorophore-Releasing Reagent and counted using time-resolved fluorescence.
131
  As can be 
noted in Figure 4, these results demonstrate very minimal differences at early time points 
between macrophage and osteoclasts, prior to day 12.  However, the large, multinucleated, 
TRAP+ cells noted at day 12 indicate osteoclast differentiation was progressing normally, as 
their morphology was clearly different compared to macrophage cultures (Figure 3.)    
RNA samples were labeled using the miRCURY LNA™ microRNA Hi-Power Labeling 
Kit Hy3™/Hy5™ and hybridized on the miRCURY LNA™ microRNA Array (7th.)  MiRNA 
levels were then interrogated using miRCURY LNA™ microRNA Arrays.  The manufacturer 
reports that the Hi-Power Labeling Kit allows highly efficient and uniform labeling, the 
hybridization and washing steps are fully automated, allowing for excellent reproducibility and 
arrays are scanned in an ozone-free environment to minimize day to day variation.  P-values and 
Bonferroni correction were calculated for maximum change of expression for each miRNA.  
This was not necessary the overall change, from day 0 to 12, as the maximum change may have 
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occurred between two different time points.  Table 1 lists the 69 miRNAs that were differentially 
expressed throughout osteoclast differentiation as per Bonferroni correction (p<0.5).  Using these 
69 miRNAs, ANCOVA p-values were then calculated for the change in expression value for 
each day compared to the baseline, day 0.  Figure 5 shows that from day 1 to day 12, the number 
of miRNAs differentially expressed as compared to baseline increases from 58 on day1 to 64 on 
day 3, 67 on day 6 and 69 miRNAs on day 12.  Further analysis of target mRNAs was limited to 
those with an expression level (average Hy3) within a range of 7.5-14.5 as well as a fold change 
of at least 2 (log fold change >1.0, Exicon.)  Table 2 shows the 27 remaining miRNAs from the 
original list of 69 which were stated to be differentially expressed based on Bonferroni correction 
alone.  Table 2 lists the miRNAs in order of log fold change, with those at the top being those 
that were up-regulated with the greatest log fold change and those at the bottom being those that 
were down-regulated with the greatest log fold change.  The negative value indicates down-
regulation of the particular miRNA.  15 of 27 miRNAs were up-regulated throughout the 
differentiation of osteoclasts.  These include miR-4732-5p, miR-146a-5p, miR-3940, miR-4497, 
miR-146b-5p, miR-193a-3p, miR-378a-3p, miR-378d, miR-1246, miR-4456, miR-3182, miR-
29a-3p, miR-22-3p, miR-378c and miR-3676-5p.  12 of the 27 miRNAs were down-regulated 
throughout osteoclastogenesis and include miR-101-3p, miR-103a-3p, miR-191-5p, miR-142-5p, 
miR-30c-5p, miR-142-3p, miR-92a-3p, miR-15a-5p, miR-15b-5p, miR-16-5p, miR-106b-5p and 
miR-223-3p.  Figures 6a-f display the signal or Hy3 expression from day 0-12 for six of these 
miRNAs; miR-146b-5p, miR-146a-5p, miR-29a-3p and miR-1246 which have been up-
regulated, and miR-223-3p and miR-106b-5p which have been down-regulated.  While the 
expression levels of miR-1246 decrease after an initial increase from day 0 to 3, the overall 
change is an increase and so this miRNA is listed as up-regulated.  Values for all four donors 
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have been entered at each time point and the error bars show mi deviation at each time point.  
For a given miRNA, the patterns in expression level change have been fairly consistent between 
the donors.   
The top 69 differentially expressed miRNAs, as per Bonferroni correction only, were 
entered into Ingenuity
®
 Pathway Analysis.  Figure 7 shows the associated network functions in 
relation to cancer, gastrointestinal disease, cellular assembly and organization.  MiRNAs miR-
455-5p, miR-455, miR-22-3p, miR-210-3p, miR-29, mir-29b-3p, miR-1237-5p, miR-378 and 
miR-378a-3p are shown in this network along with the relationships with the other molecules in 
the network.  Table 3 lists the genes and their function.  The majority of these listed functions 
relate cellular proliferation, differentiation and growth, and in some cases, apoptosis.   
Target mRNAs were investigated from 27 differentially expressed miRNAs, as per p-
value with Bonferroni correction, and limiting for those with expression value within range of 
7.5-14.5 and fold change >2.  Targets were initially identified with the miRWALK database, 
allowing for comparison with 3 other publically available databases.  Table 4 includes a list of 
these 27 top differentially expressed miRNAs and target mRNAs noted in miRWALK with a 
brief gene description.  Only those mRNAs that were noted to have functions or roles in 
osteoclastogenesis, and were predicted targets in at least 3 of the 4 databases were included.  
When a search did not yield information on targets for a given miRNA on miRWALK, the 
miRDB database was used; these mRNAs are marked with an asterisk, as miRDB does not 
examine agreement between multiple programs as miRWALK does.  Each of the top 30 mRNA 
targets was investigated for each miRNA, whether in miRWALK or miRDB.  After this, a 
manual search was conducted for particular mRNAs known to be associated with 
osteoclastogenesis.  Several of the miRNAs in this table have “unknown” listed under the mRNA 
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column, including miR-3940-5p, miR-4497, miR-378d, miR-378c, miR-3676-5p and miR-191-
5p.  For these miRNAs, the investigation did not yield any predicted mRNA targets that were 
associated with osteoclastogenesis.  Several of the mRNA targets are listed as predicted targets 
for multiple miRNAs.  For example, FOSL2 is targeted by both miR-193a-3p and miR-92a-3p, 
and the members of the FOS gene family have been implicated in regulatory roles of cell 
proliferation and differentiation.  These are not the only miRNAs that target FOSL2; the miRDB 
database indicates that FOSL2 is predicted to target 34 different miRNAs.  FOS and FOSB are 
also members of this same gene family and are targeted by miR-101-3p and miR-142-5p, 
respectively.  TGFBR1, which is predicted to be targeted by 151 miRNAs in miRDB, was 
targeted by 6 of our top 27 miRNAs, including miR-193a-3p, miR-3182, miR-22-3p, miR-101-
3p, miR-142-5p and miR-142-3p.  ITGB3 was predicted to be targeted by miRNAs in miRDB, 
and was targeted by 4 of our top 27 miRNAs, including miR-146b-5p, miR-193a-3p, miR-1246 
and miR-92a-3p.  Both of these genes were proposed to have key roles in RANKL and M-CSF 
induced differentiation of osteoclasts as they interacted with many proteins and were noted to be 
key nodes in signaling transduction.
132
 
Figures 8 and 9 display the significantly differentially expressed miRNAs that have been 
up-regulated and down-regulated, respectively.  The least square means were calculated using 
the expression values for each donor at every time point for these miRNA.  Among the donors, 
the expression values for a given miRNA at each time point were closely related (data not 
shown.)  Both figures display that the levels of expression (average Hy3) at each time point vary 
for the different miRNAs, and for a given miRNA, the expression values vary at different time 
points.  Note that the peak or minimum expression values do not always occur at day 12.   
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Discussion 
 
The present study examines the miRNA profile and predicted mRNA targets throughout 
the process of osteoclastogenesis.  Peripheral blood monocytes were isolated from 4 
independent, healthy, human donors and cultured in media containing M-CSF and sRANKL to 
induce osteoclastogenesis.  Day 0 monocytes and macrophages cultured with M-CSF and no 
sRANKL were used as for controls for comparison, particularly in confirmation of 
differentiation to osteoclasts.  Flow cytometry was used to phenotype monocytes and 
macrophages, confirming the differentiation to macrophages by comparing day 0 to day 6 
samples.  At day 6, samples were both CD14 and CD86+ but negative for CDw93, although the 
day 0 samples were CDw93+.  These findings were typical of differentiation to macrophages as 
CDw93 expression is typically lost in monocyte-to-macrophage differentiation.  TRAP staining 
and the Osteolyse™ assay were then used to confirm differentiation to osteoclasts in the 
appropriate samples.  In comparison of TRAP stain for samples at days 0, 3, 6 and 12; TRAP 
positivity increases with expected osteoclast differentiation.  The Osteolyse™ assay was 
performed on days 3, 6 and 12 on both samples cultured for macrophage differentiation and 
those cultured for osteoclast differentiation.  Interestingly, there was little to no difference up to 
day 12, between macrophages and osteoclasts.  This pattern was consistent in the Osteolyse™ 
data for all 4 donors.  Cody et al. 2011 proposed a different method for generation of osteoclasts 
in vitro, by differentiating osteoclasts from bone marrow cells.  However, in this study, although 
they confirmed TRAP+ staining at an earlier time point, they confirmed the presence of 
resorption pits using scanning electron microscopy, upon the devitalized bovine cortical bone 
their osteoclast precursors were seeded upon.  Cody et al. maintained cultures in osteoclastogenic 
media for 18 days before examining for resorption pits to confirm function.
133
  One possible 
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explanation for the similarity in Osteolyse™ data between our samples may be the time point at 
which we conducted the assay, which was a maximum of 12 days.  However, the large, 
multinucleated, TRAP+ cells noted at day 12 clearly indicate osteoclast differentiation was 
progressing normally (Figure 3.) 
Following total RNA isolation, samples were randomly labeled 1-36 to minimize bias 
during the labeling of samples and hybridization onto the arrays.  Quality control measures were 
repeated by Exiqon to confirm quantity and integrity of the RNA.  In addition, Exiqon services 
examined the number of miRNAs above background threshold.  Numbers were found to be 
within the expected range and were found to be comparable for all samples, indicating 
comparable quality of samples.   
Microarray technology has been used successfully in the past in genomic and biologic 
research
71, 134
 and has been found to enhance binding affinity as well as improve specificity and 
sensitivity of miRNA detection.
71, 135
  To account for high throughput experimental procedures, 
such as microarrays, being prone to giving false positive results, Exiqon Services provided p-
values which have been corrected for multiple testing by Benjamini and Hochberg adjustment 
method.  Controlling for the number of false positives when a large number of statistical tests are 
completed simultaneously helps to prevent type I error, where the null hypothesis is incorrectly 
rejected.
136
  MiRNAs which were found to be significantly differentially expressed by one-way 
ANOVA test were subjected to Tukey’s ‘Honest Significant Difference’ test in order to 
determine which groups contributed the most to the significant difference.  With the analysis, 
throughout monocyte to osteoclast differentiation, 403 of 422 miRNAs analyzed were found to 
be up or down regulated, and  a subset of 219 miRNAs were shown to be significantly 
differentially expressed (p <0.05).  To increase stringency, we calculated p-values and performed 
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a Bonferroni correction.  69 miRNAs were found to be significantly, differentially expressed (p 
<0.05) between two time points within the 12 days.  MiRNAs with expression levels (Hy3) 
within a range of 7.5-14.5 and with a minimum 2-fold change were further selected before 
analyzing for target genes (Exiqon.)  27 miRNAs formed the final list of differentially expressed 
miRNAs throughout osteoclastogenesis.  It is recognized that a less stringent selection criteria 
would have revealed more miRNAs and thus targets could be investigated.  For example, miR-
210, which was listed in our 69 differentially expressed miRNA but not selected in our final 27, 
has been suggested to be involved in TNFα-regulated osteoclast differentiation.137  Future studies 
with greater numbers of replicates are required for further evaluation. 
Target selection was completed using the publically available mirWALK database, which 
allowed for comparison between multiple similar databases.  The three that were chosen for 
comparison with mirWALK were TargetScan, miRANDA and miRDB.  Such programs predict 
miRNA targets by identifying conserved complementary motifs in the 3’ UTR of target mRNAs 
and the seed sequence, or 5’ proximal end of a mature mRNA.71, 138  TargetScan139 and 
miRANDA
140
 are among the most commonly used target prediction programs.
71
  In 2006, 
Sethupathy et al. compared the performance of different computational methods, studying 84 
miRNA-target gene interactions, involving a total of 32 miRNAs.  The three algorithms 
investigated (PiCTar, TargetScan and miRANDA), identified approximately 65% of conserved, 
unbiased interactions, which were supported by experiments.
77, 141
  Although the different 
programs do have their individual false positive rates, the comparison of the predictions from the 
programs can lead to enhancement of the specificity for prediction of targets.  The combination 
of the programs could predict approximately 92% of the conserved and verified interactions 
between miRNAs and the target genes.
142
  Although this method is able to achieve high 
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probability predictions, as algorithms are combined, false negatives may become problematic, 
highlighting that the selection of algorithms is critical.
142
  Thus far, the in silico approach to 
identifying miRNA targets has been the main method, and it does allow for the identification of 
biological roles of miRNAs.
77
 
Our search through mirWALK and miRDB for target mRNAs did not yield any related to 
osteoclastogenesis for some of the miRNAs.  Although such predicted targets could not be 
determined in the present study, this does not mean they do not exist, and future research may 
ascertain osteoclast-related targets of these miRNAs.  As can be noted in Table 4, miRNAs target 
multiple mRNAs, and a given mRNA may be a target for multiple miRNAs.  This results from 
the partial complementarity with which miRNAs bind to their targets, and as this is over a short 
sequence, therein lays a challenge to the identification of target genes.
143
   
 This study has some limitations.  Although we used biological replicates (4 independent 
donors) and evaluated miRNA expression over 12 days (N=36 arrays), a greater number of 
replicates and a longer differentiation period (ex. up to 20 days) would likely reveal additional 
miRNAs important in the differentiation process.  RT-PCR validation will be required to confirm 
our array findings, in addition to functional assays (overexpression/knockdown) to confirm the 
in-silico findings.  Furthermore, as our Osteolyse™ data illustrates, the differentiation process in 
the present study yielded pre-functional osteoclasts.   
In conclusion, 27 miRNAs were differentially expressed throughout 12 day of 
osteoclastogenesis, culturing of peripheral blood monocytes in media containing M-CSF and 
sRANKL.  Several predicted targets associated with osteoclastogenesis were identified for these 
miRNA.  Further, our bioinformatics analysis revealed that many of these miRNA targeted 
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multiple mRNAs and that individual mRNAs were also targets for multiple miRNA.  It has 
previously been reported that miRNAs, such as miR-223 and miR-146a are associated with 
osteoclastogenesis
98,110  
To our knowledge, miR-378a and miR-3182, identified in this study, 
have not been reported to be associated with osteoclastogenesis in the literature.  The miRNAs 
investigated in this study may play a crucial role in osteoclastogenesis and thus bone resorptive 
disease, providing a basis for further investigations into mRNA targets, disease pathogenesis and 
possibly, future therapeutic targets.   
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FIGURE 1 
 
 
 
 
 
 
Figure 1: Phenotyping of day 0 monocytes and day 6 cells cultured with M-CSF using Flow Cytometry with FITC 
to confirm differentiation to macrophages.  Red- unstained, blue- isotype control, green- sample.  Both samples are 
CD14 and CD86 positive.  Only the monocytes are CD93+ which is consistent with differentiation to macrophages 
in the day 6 samples cultured with M-CSF. 
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FIGURE 2 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
 
Figure 2: Representative TRAP stain of differentiating osteoclasts (20x magnification.)  A) Day 0 monocytes B) 
Day 3 C) Day 6  D) Day 12 noting progressively larger cells and gain in staining intensity.  Note multinucleated 
morphology of day 12 cultures. 
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FIGURE 3 
 
 
 
 
 
 
 
 
 
 
Figure 3: Representative cells at two time points.  A) Day 0 monocyte  B) Day 12 osteoclast, note multinucleated 
cells  C) Day 12 osteoclast note large, multinucleated cell with ruffled borders. 
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FIGURE 4 
 
 
Figure 4: Representative Osteolyse™ results; performed on days 3, 6 and 12 on macrophage and osteoclast lineage 
samples.  Note little to no difference between time points and between macrophages and osteoclasts up to day 12.  
Pattern of results was found to be consistent for all four donors. 
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TABLE 1 
 
miRNA 
p-value 
Bonferroni 
 
miRNA 
p-value 
Bonferroni 
hsa-miR-125a-5p <.0001 hsa-miR-30c-5p 0.0015 
hsa-miR-223-3p <.0001 hsa-miR-191-5p 0.0017 
hsa-miR-106b-5p <.0001 hsa-miR-940 0.0023 
hsa-miR-146b-5p <.0001 hsa-miR-642b-5p 0.0027 
hsa-miR-92a-3p <.0001 hsa-miR-378f 0.0028 
hsa-miR-581 <.0001 hsa-miR-199b-5p 0.0031 
hsa-miR-103a-3p <.0001 hsa-miR-30e-3p 0.0035 
hsa-miR-25-3p <.0001 hsa-miR-455-5p 0.0039 
hsa-miR-378a-3p <.0001 hsa-miR-142-5p 0.0047 
hsa-miR-301a-3p <.0001 hsa-miR-18b-5p 0.0053 
hsa-miR-15a-5p <.0001 hsa-miR-22-3p 0.0054 
hsa-miR-193a-3p <.0001 hsa-miR-3940-5p 0.0055 
hsa-miR-378c <.0001 hsa-miR-130a-3p 0.0058 
hsa-miR-454-3p <.0001 hsa-miR-4497 0.0066 
hsa-miR-34a-5p <.0001 hsa-miR-3178 0.0068 
hsa-miR-378d <.0001 hsa-miR-101-3p 0.0073 
hsa-miR-146a-5p <.0001 hsa-miR-3613-5p 0.0094 
hsa-miR-99b-3p <.0001 hsa-miR-20b-5p 0.011 
hsa-miR-339-5p <.0001 hsa-miR-340-5p 0.0137 
hsa-miR-193a-5p <.0001 hsa-miR-26a-5p 0.0151 
hsa-miR-140-3p 0.0001 hsa-miR-365a-3p/hsa-miR-365b-3p 0.0187 
hsa-miR-3182 0.0001 hsa-miR-107 0.0187 
hsa-miR-29a-3p 0.0001 hsa-miR-660-3p 0.0192 
hsa-miR-425-5p 0.0003 hsa-miR-33a-5p 0.0206 
hsa-miR-363-3p 0.0003 hsa-miR-4521 0.0223 
hsa-miR-15b-5p 0.0003 hsa-miR-423-3p 0.0226 
hsa-miR-4732-5p 0.0004 hsa-miR-4780 0.0238 
hsa-miR-17-3p 0.0005 hsa-miR-378e 0.026 
hsa-miR-130b-3p 0.0007 hsa-miR-4488 0.0262 
hsa-miR-142-3p 0.001 hsa-miR-3676-5p 0.0318 
hsa-miR-210 0.0011 hsa-miR-16-5p 0.0322 
hsa-miR-1246 0.0011 hsa-miR-338-3p 0.036 
hsa-miR-500a-5p 0.0011 hsa-miR-197-3p 0.0469 
hsa-miR-4456 0.0011 hsa-miR-532-3p 0.0498 
hsa-miR-9-5p 0.0012     
 
Table 1: 69 miRNAs found to be significantly differentially expressed throughout osteoclast differentiation.  
Benjamini and Hochberg adjustment applied (p <0.05). 
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FIGURE 5 
 
 
 
 
 
 
 
 
Figure 5: Number of miRNAs differentially expressed in M-CSF + sRANKL cells at each time point (Bonferroni p 
<0.05) for expression for expression change of miRNA within 12 days and ANCOVA (p <0.05) at specific time 
point compared to baseline (day 0) 
 
 
 
 
 
 
 
 
 
 
 
 
1 3 6 1 2
0
2 0
4 0
6 0
8 0
M iR N A s  D iffe re n t ia lly  E x p re s s e d  in  M -C S F  + s R A N K L  C e lls
D a y s
N
u
m
b
e
r
 m
iR
N
A
s
38 
 
TABLE 2 
 
miRNA logFc p-value 
(Bonferroni) 
Avg. Hy3 
hsa-miR-4732-5p 4.183 0.0004 7.529 
hsa-miR-146a-5p 3.274 <.0001 8.034 
hsa-miR-3940-5p 3.038 0.0055 9.132 
hsa-miR-4497 2.82 0.0066 7.589 
hsa-miR-146b-5p 2.408 <.0001 8.226 
hsa-miR-193a-3p 2.385 <.0001 8.324 
hsa-miR-378a-3p 2.106 <.0001 8.907 
hsa-miR-378d 2.065 <.0001 7.915 
hsa-miR-1246 1.78 0.0011 11.648 
hsa-miR-4456 1.663 0.0011 9.321 
hsa-miR-3182 1.658 0.0001 10.544 
hsa-miR-29a-3p 1.59 0.0001 8.482 
hsa-miR-22-3p 1.398 0.0054 10.161 
hsa-miR-378c 1.339 <.0001 7.924 
hsa-miR-3676-5p 1.011 0.0318 8.690 
hsa-miR-101-3p -1.252 0.0073 7.879 
hsa-miR-103a-3p -1.273 <.0001 8.975 
hsa-miR-191-5p -1.312 0.0017 8.589 
hsa-miR-142-5p -1.312 0.0047 9.353 
hsa-miR-30c-5p -1.335 0.0015 8.222 
hsa-miR-142-3p -1.57 0.001 11.154 
hsa-miR-92a-3p -1.618 <.0001 7.807 
hsa-miR-15a-5p -2.001 <.0001 9.515 
hsa-miR-15b-5p -2.34 0.0003 8.217 
hsa-miR-16-5p -2.353 0.0322 9.808 
hsa-miR-106b-5p -2.708 <.0001 8.261 
hsa-miR-223-3p -3.744 <.0001 10.224 
 
Table 2: 27 miRNAs found to be significantly differentially expressed throughout osteoclast differentiation.  
Bonferroni correction applied to p-values.  MiRNAs listed by logFc with positive values representing up-regulation 
and negative values representing down-regulation.  P-values and expression intensity (average Hy3) also displayed 
as selection for a fold change >2 and expression value within 7.5-14.5 range completed. 
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FIGURE 6 
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Figure 6: Signal intensity or Hy3 expression at day 0, 1, 3, 6 and 12 for six significantly differentially expressed 
miRNAs.  Error bars display standard deviation at each time point.  Levels of expression value are fairly consistent 
between the 4 donors 
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FIGURE 7 
 
 
 
Figure 7: 27 Network with associated functions in cancer, gastrointestinal disease, cellular assembly and 
organization as determined by Ingenuity
®
 Pathway Analysis, following input of differentially expressed miRNAs 
during osteoclast differentiation (Bonferroni p <0.05).  Green shading indicated down-regulation of miRNA 
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 TABLE 3 
 
Gene Full name Role in Cell 
MNT 
 
MAX dimerization protein proliferation, apoptosis, cell cycle 
progression, function, aging, 
survival, transformation, 
expansion, quantity, development 
ACVR1B Activin A receptor, type IB differentiation, apoptosis, G1/S 
phase transition, growth 
TP53I11 Tumor protein p53 inducible protein 11 proliferation, lysis 
RAS Rat sarcoma transformation, proliferation, 
growth, differentiation, apoptosis, 
activation in, colony formation, 
senescence, migration, cell cycle 
progression 
MAP2K2 Mitogen-activated protein kinase kinase 2 cell death, transformation, 
migration, M phase, cell cycle 
progression, cell spreading, 
growth, apoptosis, proliferation, 
replication 
COL4A1 Collagen, type IV, alpha 1 formation, abnormal morphology, 
migration, phosphorylation in, 
anoikis, development, structural 
integrity, transdifferentiation, 
transmigration, proliferation 
Calcifediol  expression in, apoptosis, cell 
death, function, development, 
action in, differentiation, 
proliferation 
KAT6A K(lysine) acetyltransferase 6A number, abnormal morphology, 
differentiation, lack expression in 
several diseases 
COL5A2 Collagen, type V, alpha 2 organization, abnormal 
morphology 
DUSP2 Dual specificity phosphatase 2 pluripotency, activation in, 
function, tumorigenicity, 
apoptosis 
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PDGFB Platelet-derived growth factor beta polypeptide proliferation, migration, 
transformation, expression in, 
abnormal morphology, 
chemotaxis, growth, quantity, 
activation, recruitment 
TP53I11 Tumor protein p53 apoptosis, cell cycle progression, 
proliferation, cell death, growth, 
expression in, G1 phase, 
senescence, transformation, 
survival 
TDG Thymine-DNA glycosylase demeythylation in bleeding, 
edema and several disease 
conditions 
PPIC Peptidylprolyl isomerase C (cyclophilin C) invasion, migration, replication 
ZFP36L1 ZFP36 ring finger protein-like 1 proliferation, translation, 
apoptosis 
PPM1D Protein phosphatase, Mg2+/Mn2+ dependent, 1D apoptosis, proliferation, 
dephosphorylation in, quantity, 
cell death, phosphorylation in, 
G2/M phase transition, mitosis, 
polyploidization, expression in 
several disease conditions/cancers 
PURA Purine-rich element binding protein A proliferation, number, abnormal 
morphology, quantity, translation 
in, formation, G2 phase, mitosis, 
G1 phase, size 
FAM3C Family with sequence similarity 3, member C  
FRAT2 Frequently rearranged in advanced T-cell lymphomas 2  
AGO2 Argonaute RISC catalytic component 2 expression in, binding in, growth, 
proliferation, processing in, 
accumulation in, quantity, 
assembly in, maturation in, 
invasiveness 
TCL1A T-cell leukemia/lymphoma 1A apoptosis, proliferation, 
expression in, survival, 
methylation in, maintenance, 
function in, growth, activation in, 
activation 
Tpm1 Tropomyosin 1, alpha actin capping, shape, size, 
migration, activity, maximum 
tension, contractility, formation, 
quantity 
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PMP22 Peripheral myelin protein 22 abnormal morphology, 
myelination, morphology, 
differentiation, proliferation, 
assembly, action potential, 
synaptic transmission, migration, 
cell death 
DCP2 Decapping mRNA1 degradation 
CNOT8 CCR4-NOT transcription complex, subunit 8 proliferation, repression in, 
translation 
 
Table 3: Targets noted in Figure 7 along with name and role played within cell.  Note common functions of cell 
proliferation, differentiation, morphology and apoptosis 
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TABLE 4 
miRNA mRNA Gene description 
hsa-miR-4732-5p RBPJ* recombination signal binding protein for immunoglobulin 
kappa J region 
hsa-miR-146a-5p TRAF6* TNF receptor-associated factor 6, E3 ubiquitin protein ligase 
hsa-miR-3940-5p unknown --- 
hsa-miR-4497 unknown --- 
hsa-miR-146b-5p ARF6 ADP-ribosylation factor 6 
hsa-miR-146b-5p ITGβ3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
hsa-miR-146b-5p RAC2 ras-related C3 botulinum toxin substrate 2 
hsa-miR-146b-5p IL17A interleukin 17A 
hsa-miR-193a-3p ITGβ3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
hsa-miR-193a-3p FOSL2 FOS-like antigen 2 
hsa-miR-193a-3p TGFβR1 transforming growth factor, beta receptor I 
hsa-miR-378a-3p ELK4* ETS-domain protein (SRF accessory protein 1) 
hsa-miR-378d unknown --- 
hsa-miR-1246 CTSK cathepsin K 
hsa-miR-1246 CA2 carbonic anhydrase II 
hsa-miR-1246 ANK1 ankyrin 1, erythrocytic 
hsa-miR-1246 ITGβ3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
hsa-miR-4456 ERO1Lβ* ERO1-like beta 
hsa-miR-3182 TGFβR1* transforming growth factor, beta receptor I 
hsa-miR-29a-3p BIRC2 baculoviral IAP repeat containing 2 
hsa-miR-29a-3p GSR glutathione reductase 
hsa-miR-29a-3p CA2 carbonic anhydrase II 
hsa-miR-29a-3p MEFV Mediterranean fever 
hsa-miR-22-3p TGFβR1 transforming growth factor, beta receptor I 
hsa-miR-22-3p CIC capicua transcriptional repressor 
hsa-miR-378c unknown --- 
hsa-miR-3676-5p unknown --- 
hsa-miR-101-3p TGFβR1* transforming growth factor, beta receptor I 
hsa-miR-101-3p MITF* microphthalmia-associated transcription factor 
hsa-miR-101-3p FOS* FBJ murine osteosarcoma viral oncogene homolog 
hsa-miR-103a-3p CA2* carbonic anhydrase II 
hsa-miR-103a-3p ANK1* ankyrin 1, erythrocytic 
hsa-miR-191-5p unknown --- 
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hsa-miR-142-5p CIC capicua transcriptional repressor 
hsa-miR-142-5p TGFβR1 transforming growth factor, beta receptor I 
hsa-miR-142-5p CREB1 cAMP responsive element binding protein 1 
hsa-miR-142-5p FOSB FBJ murine osteosarcoma viral oncogene homolog 
hsa-miR-30c-5p CREB1* cAMP responsive element binding protein 1 
hsa-miR-142-3p TGFβR1 transforming growth factor, beta receptor I 
hsa-miR-92a-3p DUSP10 dual specificity phosphatase 10 
hsa-miR-92a-3p CIC capicua transcriptional repressor 
hsa-miR-92a-3p MEFV Mediterranean fever 
hsa-miR-92a-3p ITGβ3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
hsa-miR-92a-3p FOSL2 FOS-like antigen 2 
hsa-miR-92a-3p MITF microphthalmia-associated transcription factor 
hsa-miR-15a-5p CA2* carbonic anhydrase II 
hsa-miR-15a-5p STXBP3* syntaxin binding protein 3 
hsa-miR-15b-5p CA2* carbonic anhydrase II 
hsa-miR-15b-5p STXBP3* syntaxin binding protein 3 
hsa-miR-16-5p CA2* carbonic anhydrase II 
hsa-miR-16-5p STXBP3* syntaxin binding protein 3 
hsa-miR-106b-5p MAP3K2* mitogen-activated protein kinase kinase 2 
hsa-miR-106b-5p CTSK* cathepsin K 
hsa-miR-223-3p KHDRBS1 KH domain containing, RNA binding, signal transduction 
associated 1 
hsa-miR-223-3p ERP29 endoplasmic reticulum protein 29 
hsa-miR-223-3p TRAP1 TNF receptor-associated protein 1 
 
Table 4: 27 miRNAs differentially expressed (Bonferroni p <0.05) with signal expression levels between 7.5-14.5 
and minimum 2-fold change.  One mRNA target associated with osteoclastogenesis is listed for each miRNA.  
An asterisk next to target indicates that it was ascertained through miRDB database (predicted by MirTarget2), 
which was done if results were not yielded through miRWALK database.  “Unknown” is noted under mRNA 
targets for tor those miRNAs for which we were unable to identify a target associated with osteoclastogenesis 
through our search. 
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FIGURE 8 
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Figure 8: miRNAs that were significantly differentially expressed and up-regulated overall.  Chart displays the 
least square means of expression values at each time point for 4 donors.  Note that peak expression levels vary by 
time point for the miRNAs and that the peak value is not always at Day 12. 
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FIGURE 9 
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Figure 9: miRNAs that were significantly differentially expressed and down-regulated overall.  Chart displays the 
least square means of expression values at each time point for 4 donors.  Note that peak expression levels vary by 
time point for the miRNAs and that the lowest expression value does not always occur at Day 12. 
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